Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc is experiencing notable advancements in its clinical drug development and commercialization efforts, with expected revenue growth projections indicating an increase to $1.3 million in 2025 and $4.5 million in 2026. The expansion of its commercial cancer center partnerships, from five to nine currently, including prestigious institutions like City of Hope and Moffitt Cancer Center, highlights its growing market presence. Additionally, the company's innovative Trans-Arterial Micro-Perfusion therapy platform positions it strategically within a high-demand market, enhancing its potential for long-term financial success.

Bears say

RenovoRx Inc. reported revenue of $0.3 million alongside a net loss of $2.9 million, reflecting ongoing financial challenges in a highly competitive and uncertain biopharmaceutical market. The company's focus on treating pancreatic cancer, which has an exceedingly low five-year survival rate of 12%, underscores the daunting clinical hurdles it faces to demonstrate the efficacy and safety of its treatments. Various risks, including balance sheet and liquidity threats, regulatory approval uncertainty, and difficulties in commercialization and reimbursement, contribute to a negative outlook for the stock's performance amidst an environment marked by investor caution towards biotech investments.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.